Cidara’s long-lasting antiviral shows promise as prophylaxis

By meeting the primary endpoint in a Phase IIb influenza prevention study, Cidara’s small molecule drug-Fc conjugate, CD388, creates a line of sight to a non-vaccine approach for preventing flu.

The data led shares of  Cidara Therapeutics Inc. (NASDAQ:CDTX) to rise 114% on Monday, representing a market cap increase of about $310 million. ...